biocon 1 1

Tag: "biocon" at medical news

Biocon to colloborate for development of Oral peptide drugs for heart diseases.

The Indian Biotech Company, Biocon to colloborate with Nobex Corporation of United States to develop a new oral peptide drug for cardiovascular diseases. The spokesperson of Biocon informed that the company has gone into global research collaboration // on Tuesday for development of peptide based product for treatment of cardiovasculoar diseases. The Biocon press release said, “The collaboration...

Biocon To Raise Its Investment In Scotland

Biocon, an Indian biotechnology company will raise its investments in Scotland which is seen to be an emerging destination for clinical development of drugs. Biocon is reported to already have // a close relationship with life sciences organizations in Scotland. There are more than 550 life sciences organizations in Scotland, employing more than 26,500 people. Scotland will serve to fill the ga...

Biocon To Shift Focus On Innovation To Accelerate Growth

Biocon Ltd, India's largest biotechnology firm, has made a paradigm shift from being a generic drug manufacturer to innovation to drive its future growth aggressively. // .."We are rapidly transforming from a generics API (active pharmaceutical ingredients) manufacturer into an innovator for developing a robust pipeline of new molecules. .."We believe this strategy will deliver strong and susta...

Kalam Dedicates New Cancer Drug Developed By Biocon

President A P J Abdul Kalam today dedicated to the nation India's first indigenously developed drug for treating head and neck cancer. // ....Kalam congratulated Biocon scientists for developing the monoclonal antibody, BioMab EGFR (epidermal growth factor receptor), which company officials said works by binding to cancer cell-specific antigens and inducing an immunological response against the...

Bayer to Market Biocon Insulin in China

Indian biotech major Biocon Ltd has roped in Bayer HealthCare to market its recombinant human insulin Insugen in the Chinese market, the company //said in a statement Wednesday. ....The Bangalore-based biotech firm plans to launch Insugen in China by 2007-08 after completing the registration trials and seeking the regulatory approvals. ...."The marketing tie-up with Bayer will be extended to ot...

Biocon Launches Anti-Cancer Drug

Biocon has launched an anti-cancer drug called Biomab-EGFR and had Shah Rukh Khan at the ceremony in Bangalore. Biocon's CMD, Ms Kiran Mazumdar-Shaw told reporters that the drug would be priced at 40 percent of what similar drugs marketed by MNCs cost.// .... "Today we join the exclusive league of MAb developers worldwide. We want to be a key player in this segment," she added. She also told the...

Biocon to Launch Anti-arthritis Drug

New Delhi: India's leading biotech firm Biocon Monday said it would launch in the next three-four years a new anti-arthritis drug which would have the potential to "be a// multi-billion dollar opportunity for the company". ...."The new molecule (T1H) which has completed phase II of clinical trials can prove to be a multi-billion opportunity for us," said Kiran Mazumdar Shaw, chairman and managin...

Biocon Unveils Renal Therapies for Kidney Disorders

India's premier biotechnology firm Biocon Ltd Thursday announced the launch of renal therapy products for treating kidney disorders and reducing// the risk of such disease. ....As the leading producer of immuno-suppressants in the subcontinent, the company has set up a nephrology division to market the new products -- Renodapt (Mycophenolate Mofeti), Tacrograf (Tacrolimus), Cyclophil Me (Cyclosp...

Biocon Net Profit Up by 15 Percent for Fiscal Year

Indian biotechnology major Biocon Ltd. Thursday announced a 15 percent surge in its profit at Rs.2 billion with a total income at Rs.9.9 billion in fiscal 2006-07. // ....The firm's expenditure on research and development, during 2006-07, also increased by 86 percent at Rs.380 million, it said in a statement. It also announced increase in dividend from 50 to 60 percent, with Rs.3 per share, as...